These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 24318540)

  • 1. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
    Niciu MJ; Ionescu DF; Richards EM; Zarate CA
    J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic Modulators for Major Depression from Theory to Clinical Use.
    McIntyre RS; Jain R
    CNS Drugs; 2024 Nov; 38(11):869-890. PubMed ID: 39150594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
    Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
    Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketamine for Major Depressive Disorder.
    Costi S
    Curr Top Behav Neurosci; 2024; 66():131-147. PubMed ID: 37922100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting glutamate signalling in depression: progress and prospects.
    Murrough JW; Abdallah CG; Mathew SJ
    Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine and other potential glutamate antidepressants.
    Dutta A; McKie S; Deakin JFW
    Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies.
    Artigas F; Celada P; Bortolozzi A
    Eur Neuropsychopharmacol; 2018 Apr; 28(4):457-482. PubMed ID: 29525411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
    Hillhouse TM; Porter JH
    Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of glutamate in the pathophysiology of major depressive disorder.
    Hashimoto K
    Brain Res Rev; 2009 Oct; 61(2):105-23. PubMed ID: 19481572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.
    Mathews DC; Henter ID; Zarate CA
    Drugs; 2012 Jul; 72(10):1313-33. PubMed ID: 22731961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
    Gerhard DM; Wohleb ES; Duman RS
    Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
    Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
    Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.
    Lener MS; Niciu MJ; Ballard ED; Park M; Park LT; Nugent AC; Zarate CA
    Biol Psychiatry; 2017 May; 81(10):886-897. PubMed ID: 27449797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants.
    Chaki S; Ago Y; Palucha-Paniewiera A; Matrisciano F; Pilc A
    Neuropharmacology; 2013 Mar; 66():40-52. PubMed ID: 22640631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
    Miller OH; Moran JT; Hall BJ
    Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A hypothesis of monoamine (5-HT) - Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery.
    Li YF
    Pharmacol Ther; 2020 Apr; 208():107494. PubMed ID: 31991195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.